Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Not yet recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 14HER2-positive Breast Cancer 2Biliary Tract Neoplasms 1Anatomic Stage IV Breast Cancer AJCC v8 1Advanced HER2-positive Breast Cancer 1

Interventions

Gemcitabine 7Cisplatin 6Oxaliplatin 5Fluorouracil 4lenvatinib 3envafolimab 3S 1 (combination) 3Capecitabine 3toripalimab 2pembrolizumab 2Leucovorin 2Irinotecan 2Folfox protocol 2tislelizumab 1tegafur-gimeracil-oteracil 1surufatinib 1pertuzumab 1mitazalimab 1durvalumab 1disitamab vedotin 1camrelizumab 1anlotinib 1Simvastatin 1Self Expandable Metallic Stents 1Bevacizumab 1Albumin-Bound Paclitaxel 1Actigraphy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Biliary Tract Neoplasms × pertuzumab × Clear all
NCT07129018 2025-08-19

Trastuzumab Rezetecan Combined With Pertuzumab and Iparomlimab and Tuvonralimab for Biliary Tract Cancer

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Phase 2 Not yet recruiting
63 enrolled
Gastrointestinal

Biliary Tract Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡